MTHFR C 677T mutation and 4G/5G PAI-1 polymorphism in patient with polycystic ovarian syndrome

Radaković, Branko and Šprem Goldštajn, Marina (2007) MTHFR C 677T mutation and 4G/5G PAI-1 polymorphism in patient with polycystic ovarian syndrome. Collegium Antropologicum, 31 (3). pp. 919-921. ISSN 0350-6134

Preview

PDF - Published Version
Download (47kB) | Preview

Official URL: https://hrcak.srce.hr/26908

Abstract

Combined oral contraceptives (Ocs) are the most commonly used androgen suppressors and the treatment of choice for menstrual dysfunction in women with polycystic ovarian syndrome (PCOs). Although OCs have remained popular due to their convenience and effectiveness, there have been continuing concerns about adverse effects. The OCs have long been known to incur and increased risk of venous thromboembolism especially in carriers of common inherited thromboembolic defects. Factor V Leiden, prothrombin factor G20210A polymorphism, MTHFR (C677T) mutation and 4G/5G polymorphism of the PAI-1 gene account for the majority of thromboembolic events in association with oral contraceptive use. The aim of the article is to present woman with unrecognized inherited thrombophilia who was treated with OCs due to PCOs signs.

Abstract in Croatian

Kombinirani oralni kontraceptivi su najčešće korišteni supresori androgena, i lijek izbora u terapiji poremećaja menstruacijskog ciklusa u žena s policističnim ovarijskim sindromom. Iako su kombinirani oralni kontraceptivi popularni zbog praktičnosti i učinkovitosti, postoji kontinuirana zabrinutost zbog neželjenih učinaka. Poznato je da kombinirani oralni kontraceptivi potiču i povećavaju rizik nastanka venskog tromboembolizma, posebice u nositeljica nasljednih tromboembolijskih defekata. Faktor V Leiden, polimorfizam protrombinskog faktora G20210A, mutacija MTHFR (C677T) i polimorfizam 4G/5G PAI-1gena povezani su s većinom tromboembolijskih dogadjaja u žena koje koriste oralnu hormonsku kontracepciju. Cilj ovog rada je prikazati ženu s neprepoznatom nasljednom trombofilijom, koja je liječena oralnim kontraceptivima zbog znakova policističnog ovarijskog sindroma.

Item Type:

Article

MeSH:

Contraceptives, Oral, Combined - adverse effects - contraindications ; Methylenetetrahydrofolate Reductase (NADPH2) - genetics ; Plasminogen Activator Inhibitor 1 - genetics ; Polycystic Ovary Syndrome - drug therapy ; Thrombophilia - genetics ; Adult ; Female ; Genetic Predisposition to Disease ; Humans ; Hyperhomocysteinemia - genetics ; Thromboembolism - chemically induced - genetics - prevention & control

Departments:

Katedra za ginekologiju i opstetriciju

Depositing User:

Boris Čičovački

Status:

Published

Creators: